{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:55:17Z","timestamp":1794434117850,"version":"4.9.1"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Deputyship for Research and Innovation of the Ministry of Education in Saudi Arabia","award":["988"],"award-info":[{"award-number":["988"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11,29]]},"abstract":"<jats:p>\n                    Type 2 diabetes mellitus (T2DM) is a chronic disease that affects millions of people worldwide. Metformin is the optimal initial therapy for patients with T2DM. Genetic factors play a vital role in metformin response, including variations in drug efficacy and potential side effects. To determine the effects of genetic variants of multidrug and toxin extrusion protein 2 (MATE2), ataxia telangiectasia mutated (ATM), and serine\/threonine kinase 11 (STK11) genes on metformin response in a cohort of Saudi patients. This prospective observational study included 76 T2DM newly diagnosed Saudi patients treated with metformin monotherapy and 80 control individuals. Demographic data, lipid profiles, creatinine levels, and hemoglobin A1c (HbA1c) levels were collected before and after treatment. All participants were genotyped for 5 single-nucleotide polymorphisms (SNPs), including rs4621031, rs34399035, rs2301759, rs1800058, and rs11212617, using TaqMan R genotyping assays. This study included 156 subjects. The subjects\u2019 mean\u2005\u00b1\u2005SD age was 50.4\u2005\u00b1\u200510.14 years. The difference in HbA1c levels in T2DM after treatment ranged from \u22121.20% to 8.8%, with a mean value of 0.927\u2005\u00b1\u20051.73%. In general, 73.7% of the patients with T2DM showed an adequate response to metformin (HbA1c\u2005&lt;\u20057%). STK11 (rs2301759) significantly affects the response to metformin in T2DM patients. In the rs2301759 single-nucleotide polymorphisms, the prevalence of an adequate response to metformin was significantly higher among patients with C\/C and T\/C genotypes than among non-responders (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.021). However, no statistically significant associations were observed for the other tested SNPs. Our study provides evidence of an association between STK11 (rs2301759) and response to metformin in Saudi patients with T2DM. The need for targeted studies on specific gene-drug associations is emphasized, and further studies with a larger population should be conducted.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000040684","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T16:01:58Z","timestamp":1732896118000},"page":"e40684","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes"],"prefix":"10.1097","volume":"103","author":[{"given":"Huda M.","family":"AlKreathy","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhhakim A.","family":"Alzahrani","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"},{"name":"Department of Clinical Pharmacy, Medical Affairs, Al-Baha Health Cluster, Al-Baha, Saudi Arabia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Esmat","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-5471","authenticated-orcid":false,"given":"Zoheir A.","family":"Damanhouri","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250503","first-page":"1","article-title":"A modern review of diabetes mellitus: an annihilatory metabolic disorder.","volume":"3","author":"Deepthi","year":"2017","journal-title":"J In Silico In Vitro Pharmacol"},{"key":"R2-20250503","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/trstmh\/try124","article-title":"The double burden of diabetes and global infection in low and middle-income countries.","volume":"113","author":"Dunachie","year":"2019","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R3-20250503","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/apha.12644","article-title":"Metformin is not just an antihyperglycaemic drug but also has protective effects on the vascular endothelium.","volume":"219(","author":"Triggle","year":"2017","journal-title":"Acta physiologica"},{"key":"R4-20250503","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s13679-019-00335-3","article-title":"Metformin: mechanisms in human obesity and weight loss.","volume":"8","author":"Yerevanian","year":"2019","journal-title":"Curr Obes Rep"},{"key":"R5-20250503","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cmet.2023.03.014","article-title":"Metformin triggers a kidney GDF15- dependent area postrema axis to regulate food intake and body weight.","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab"},{"key":"R6-20250503","article-title":"Pharmacogenetics of efficiency and tolerance of the peroral antidiabetic drug metformin [doctoral thesis].","author":"Zaharenko","year":"2015","journal-title":"Riga: University of Latvia, Riga, Latvia"},{"key":"R7-20250503","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.xphs.2017.04.078","article-title":"Transporters involved in metformin pharmacokinetics and treatment response.","volume":"106","author":"Liang","year":"2017","journal-title":"J Pharm Sci"},{"key":"R8-20250503","doi-asserted-by":"crossref","first-page":"333","DOI":"10.18433\/jpps30865","article-title":"Pharmacokinetics and toxicokinetics roles of membrane transporters at kidney level.","volume":"23","author":"Veiga-Matos","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"R9-20250503","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc18-2182","article-title":"Variation in the plasma membrane monoamine transporter (PMAT)(encoded by SLC29A4) and organic cation transporter 1 (OCT1)(encoded by SLC22A1) and gastrointestinal intolerance to metformin in type 2 diabetes: an IMI DIRECT study.","volume":"42","author":"Dawed","year":"2019","journal-title":"Diabetes Care"},{"key":"R10-20250503","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s13300-020-00922-x","article-title":"Pharmacogenomic studies of current antidiabetic agents and potential new drug targets for precision medicine of diabetes.","volume":"11","author":"Zeng","year":"2020","journal-title":"Diabetes Ther"},{"key":"R11-20250503","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/164_2021_450","article-title":"Genetic and epigenetic regulation of organic cation transporters.","volume":"266","author":"K\u00f6lz","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"R12-20250503","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1016\/j.xphs.2023.05.008","article-title":"computational modelling of paracellular diffusion and OCT3 mediated transport of metformin in the perfused human placenta.","volume":"112","author":"Lofthouse","year":"2023","journal-title":"J Pharm Sci"},{"key":"R13-20250503","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40262-020-00896-w","article-title":"A comprehensive whole-body physiologically based pharmacokinetic drug\u2013drug\u2013gene interaction model of metformin and cimetidine in healthy adults and renally impaired individuals.","volume":"59","author":"Hanke","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R14-20250503","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2016.03.020","article-title":"Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug\u2013drug interactions.","volume":"88","author":"Burt","year":"2016","journal-title":"Eur J Pharm Sci"},{"key":"R15-20250503","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1002\/jps.24113","article-title":"Enzyme-transporter-mediated drug interactions with small molecule tyrosine kinase inhibitors.","volume":"103","author":"Shao","year":"2014","journal-title":"J Pharm Sci"},{"key":"R16-20250503","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s40262-016-0472-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of antihyperglycemic medications in children and adolescents with Type 2 Diabetes Mellitus.","volume":"56","author":"Akhlaghi","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R18-20250503","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/bdd.2382","article-title":"Identification and characterization of an endogenous biomarker of the renal vectorial transport (OCT2-MATE1).","volume":"45","author":"Ma","year":"2024","journal-title":"Biopharm Drug Dispos"},{"key":"R19-20250503","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1515\/dmpt-2018-0030","article-title":"Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.","volume":"33","author":"Raj","year":"2018","journal-title":"Drug Metab Personalized Ther"},{"key":"R20-20250503","first-page":"2099","article-title":"A comparison between metformin immediate-release and extended-release: a review.","volume":"140","author":"Alshadfan","year":"2022","journal-title":"BNHS"},{"key":"R21-20250503","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/pedi.12953","article-title":"Rapid progression of type 2 diabetes and related complications in children and young people\u2014A literature review.","volume":"21","author":"Barrett","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"R22-20250503","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jegh.2017.10.001","article-title":"Incidence and prevalence rates of diabetes mellitus in Saudi Arabia: AN overview.","volume":"7","author":"Alotaibi","year":"2017","journal-title":"J Epidemiol glob health"},{"key":"R23-20250503","article-title":"HEARTS D: diagnosis and management of type 2 diabetes.","year":"2020"},{"key":"R24-20250503","doi-asserted-by":"crossref","first-page":"279","DOI":"10.7326\/M16-1860","article-title":"Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline update from the American College of Physicians.","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"key":"R25-20250503","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10238-014-0283-8","article-title":"The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study.","volume":"15","author":"Mahrooz","year":"2015","journal-title":"Clin Exp Med"},{"key":"R26-20250503","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.2337\/db13-1367","article-title":"Metformin pharmacogenomics: current status and future directions.","volume":"63","author":"Pawlyk","year":"2014","journal-title":"Diabetes"},{"key":"R27-20250503","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.phrs.2017.01.023","article-title":"Sex-gender-related therapeutic approaches for cardiovascular complications associated with diabetes.","volume":"119","author":"Campesi","year":"2017","journal-title":"Pharmacol Res"},{"key":"R28-20250503","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2021.12.012","article-title":"Why does obesity cause diabetes?","volume":"34","author":"Klein","year":"2022","journal-title":"Cell Metab"},{"key":"R29-20250503","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/17512433.2022.2118714","article-title":"Effects of single-nucleotide polymorphism on the pharmacokinetics and pharmacodynamics of metformin.","volume":"15","author":"Li","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"key":"R31-20250503","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2217\/pgs.14.21","article-title":"An update on the pharmacogenomics of metformin: progress, problems and potential.","volume":"15","author":"Todd","year":"2014","journal-title":"Pharmacogenomics"},{"key":"R32-20250503","first-page":"850","article-title":"Allele and genotype frequency of a genetic variant in ataxia telangiectasia mutated gene affecting glycemic response to metformin in South Indian population.","volume":"18","author":"ilvanathan","year":"2014","journal-title":"IJEM"},{"key":"R33-20250503","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/FPC.0b013e32834c0010","article-title":"The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.","volume":"21","author":"Christensen","year":"2011","journal-title":"Pharmacogenet Genomics"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:02:20Z","timestamp":1746302540000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":31,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040684","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]}}}